Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Holding JNJ?
Track your performance easily
Earnings Data
Report Date
Jan 22, 2025Before Open Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$2.02Last Year’s EPS
$2.29Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 15, 2024
|% Change Since: -10.44%
|Next Earnings Date:Jan 22, 2025
Earnings Call Sentiment|Neutral
Johnson & Johnson reported robust sales growth and pipeline advancements in Q3 2024, particularly in Innovative Medicine and MedTech segments. However, earnings were impacted by legal settlement costs and challenges in the Asia Pacific region. Despite these challenges, the company remains confident in its growth trajectory.Company Guidance
During Johnson & Johnson's Q3 2024 earnings call, the company provided updated guidance highlighting strong operational sales growth and adjusted operational EPS expectations. Johnson & Johnson increased their adjusted operational sales growth guidance to a range of 5.7% to 6.2%, with a midpoint of 6%, driven by robust performance in both their Innovative Medicine and MedTech segments. The company reported a 6.3% operational sales increase in Q3, with worldwide sales reaching $22.5 billion. They also raised their full-year operational sales growth target to 6.3% to 6.8%, reflecting confidence in their strategic acquisitions and pipeline advancements. Despite facing headwinds in the Asia Pacific region, particularly in China, and the impact of the talc litigation settlement proposal, Johnson & Johnson adjusted their operational EPS guidance to $9.91, maintaining a positive outlook for 2025 and beyond.Strong Sales Growth
Johnson & Johnson delivered 6.3% operational sales growth in Q3 2024, with notable strength in Innovative Medicine and MedTech segments.
Innovative Medicine Performance
Innovative Medicine reported over $14 billion in sales for the second consecutive quarter, with 11 key brands growing double digits. DARZALEX reached $3 billion in sales in a single quarter.
MedTech Expansion
MedTech sales increased by 6.4%, driven by acquisitions such as Shockwave and Abiomed, leading to double-digit growth in the Cardiovascular segment.
Pipeline Advancements
Significant pipeline progress with five major U.S. and EU approvals, including RYBREVANT for lung cancer and TREMFYA for ulcerative colitis.
Positive Free Cash Flow
Year-to-date free cash flow was approximately $14 billion compared to $12 billion last year.
---
JNJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JNJ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 15, 2024 | $160.31 | $162.79 | +1.55% |
| Jul 17, 2024 | $148.68 | $154.16 | +3.69% |
| Apr 16, 2024 | $144.15 | $141.08 | -2.13% |
| Jan 23, 2024 | $157.48 | $154.90 | -1.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Johnson & Johnson (JNJ) report earnings?
Johnson & Johnson (JNJ) is schdueled to report earning on Jan 22, 2025, Before Open Not Confirmed.
What is Johnson & Johnson (JNJ) earnings time?
Johnson & Johnson (JNJ) earnings time is at Jan 22, 2025, Before Open Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JNJ EPS forecast?
JNJ EPS forecast for the fiscal quarter 2024 (Q4) is $2.02.
---
